Clinical trials: Autism, completed
Autism
Safety of L1-79 in Adolescent and Adult Males With Autism
This is a five-arm designed to assess the safety of L1-79 that incorporates 15 prospectively randomized, placebo controlled patients and 5 open label patients at either 100 tid (three times daily) or 200 tid dosing for 28 days.
- Trial name
- NCT02947048
- Testing
- L1-79
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Yamo Pharmaceuticals LLC
Autism Spectrum Disorder
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD.
- Trial name
- NCT05081245
- Testing
- ML-004 (IR)/(ER) tablet
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 168 people
- Sponsor
- MapLight Therapeutics
Sleep Disorders, Autism Spectrum Disorder
Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders
The purpose of this study is to verify the efficacy of NPC-15 (melatonin 1 mg/d or 4 mg/d) versus placebo to sleep latency with electronic sleep diaries.
- Trial name
- NPC-15-5 (NCT02757066)
- Testing
- NPC-15 Granules Lower Dose, NPC-15 Granules Higher Dose
- Volunteers
- 196 people
- Sponsor
- Nobelpharma
Autism Spectrum Disorder
Cognoa ASD Diagnosis Aid Validation Study
The primary objective of this study is to collect data to ascertain the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of the current version of the Cognoa diagnostic device.
- Trial name
- NCT04151290
- Testing
- Cognoa ASD diagnostic device
- Where
- 16 sites in United States
- Volunteers
- 711 people
- Sponsor
- Cognoa, Inc.
Autism Spectrum Disorder
Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort
The purpose of this study is to evaluate the utility of and to clinically validate the Autism Behavior Inventory (ABI) in measuring clinical symptoms of Autism Spectrum Disorder (ASD) compared with other gold standard measures.
- Trial name
- NCT02668991
- Where
- 9 sites in United States
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Autism Spectrum Disorder
Transcranial Photobiomodulation for Reducing Autism Symptoms in Children - Open Label Study (TPBMASDOL)
The hypothesis of the study is that photobiomodulation reduces symptoms of autism. Participants will be children between the ages of 2 and 7, who have been diagnosed with moderate to severe autism.
- Trial name
- NCT06359080
- Testing
- Cognilum TM: Light Treatment Condition
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- JelikaLite LLC
Autistic Disorder
A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
The objective of this study is to investigate the efficacy and safety of aripiprazole orally administered over a period of 8 weeks in pediatric patients with Autistic Disorder
- Trial name
- NCT01617447
- Testing
- Aripiprazole
- Where
- 5 sites in Japan
- Volunteers
- 92 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Rett Syndrome
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.
- Trial name
- NCT01703533
- Testing
- NNZ-2566
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neuren Pharmaceuticals Limited
Fragile X Syndrome
Biomarker and DNA Collection in Subjects Participating in Protocol 22003
The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003 will be offered participation in 22003A which will evaluate secreted protein before and after treatment with STX209 and…
- Trial name
- NCT00892580
- Testing
- STX209
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Seaside Therapeutics, Inc.
Autism
Safety and Efficacy of Stem Cell Therapy in Patients With Autism
Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by social interaction abnormalities, impaired verbal and non-verbal communication, and repetitive, obsessive behavior, while the therapeutic…
- Trial name
- NCT01343511
- Testing
- human cord blood mononuclear cells, human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Autism Spectrum Disorder
Double Blind Trial in Children With Autism Spectrum Disorder
This study investigated the safe and efficacious use of suramin as a novel treatment for ASD by testing two suramin doses vs placebo
- Trial name
- NCT06058962
- Testing
- Suramin Sodium
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Paxmedica
Autistic Disorder in Children and Adolescents
A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder
The purpose of this study is to evaluate the efficacy of risperidone compared with placebo in children and adolescents with irritability associated with autistic disorder.
- Trial name
- NCT01624675
- Testing
- Risperidone
- Where
- 17 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Janssen Pharmaceutical K.K.
ADHD, Autism
Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders
A study to assess pharmacokinetics, safety and tolerability of brexpiprazole in children ages 6 to <13 years with CNS disorders.
- Conditions
- ADHD, Autism, Bipolar I Disorder, Conduct Disorder
- Trial name
- NCT03292848
- Testing
- Brexpiprazole
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Autism
Lurasidone Pediatric Pharmacokinetics Study
This is a Phase 1, open-label, multicenter, single and multiple ascending lurasidone dose study in subjects from 6 to 17 years old with schizophrenia spectrum, bipolar spectrum, autistic spectrum disorder, or other psychiatric…
- Trial name
- NCT01620060
- Testing
- Lurasidone
- Where
- 10 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sumitomo Pharma America, Inc.
DCild Development Disorders, Pervasive, Autistic Disorder
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)
The purpose of the study is to evaluate the effectiveness of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral symptoms in children with Pervasive Developmental Disorders…
- Conditions
- DCild Development Disorders, Pervasive, Autistic Disorder, Developmental Disabilities, Asperger Syndrome
- Trial name
- NCT00261508
- Testing
- risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Ortho Inc., Canada
Autism Spectrum Disorder (ASD)
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
This study will investigate the efficacy, safety, tolerability, and pharmacokinetics of RO7017773 in participants aged 15-45 years who have been diagnosed with ASD with a score of >/=50 on the Wechsler Abreviated Scale of…
- Trial name
- NCT04299464
- Testing
- RO7017773
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 104 people
- Sponsor
- Hoffmann-La Roche
Autism Spectrum Disorder
A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children
1. Study purpose: To demonstrate the superiority of AST-001 compared to placebo in improving core symptoms of autism spectrum disorder (ASD) in children with ASD. 2.
- Trial name
- NCT06333964
- Testing
- AST-001
- Where
- 11 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Astrogen, Inc.
Autism Spectrum Disorder
Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.
This is a 20-week open-label study to evaluate the safety and efficacy of full-spectrum medicinal cannabis plant extract < 0.08% THC (FEN164) in children with Autism Spectrum Disorder.
- Trial name
- NCT05516407
- Testing
- FEN164
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Fenix Innovation Group
Irritability Associated With Autistic Disorder
Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when…
- Trial name
- NCT01227668
- Testing
- Aripiprazole
- Where
- 38 sites in United States
- Volunteers
- 215 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia, Autism
Pediatric Open-Label Extension Study
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have…
- Conditions
- Schizophrenia, Autism, Bipolar Depression
- Trial name
- NCT01914393
- Testing
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed
- Where
- 88 sites in United States, Bulgaria and 13 more
- Volunteers
- 702 people
- Sponsor
- Sumitomo Pharma America, Inc.